- Home
- CCCC vs TVGN Comparison
CCCC vs TVGN Comparison
Compare CCCC & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- TVGN
- Stock Information
- Founded
- CCCC 2015
- TVGN 2020
- Country
- CCCC United States
- TVGN United States
- Employees
- CCCC N/A
- TVGN N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- TVGN Blank Checks
- Sector
- CCCC Health Care
- TVGN Finance
- Exchange
- CCCC Nasdaq
- TVGN Nasdaq
- Market Cap
- CCCC 175.1M
- TVGN 179.0M
- IPO Year
- CCCC 2020
- TVGN N/A
- Fundamental
- Price
- CCCC $2.71
- TVGN $0.87
- Analyst Decision
- CCCC Buy
- TVGN Strong Buy
- Analyst Count
- CCCC 3
- TVGN 1
- Target Price
- CCCC $8.00
- TVGN $10.00
- AVG Volume (30 Days)
- CCCC 1.2M
- TVGN 680.5K
- Earning Date
- CCCC 10-30-2025
- TVGN 08-14-2025
- Dividend Yield
- CCCC N/A
- TVGN N/A
- EPS Growth
- CCCC N/A
- TVGN N/A
- EPS
- CCCC N/A
- TVGN N/A
- Revenue
- CCCC $34,240,000.00
- TVGN N/A
- Revenue This Year
- CCCC N/A
- TVGN N/A
- Revenue Next Year
- CCCC N/A
- TVGN N/A
- P/E Ratio
- CCCC N/A
- TVGN N/A
- Revenue Growth
- CCCC 16.55
- TVGN N/A
- 52 Week Low
- CCCC $1.09
- TVGN $0.26
- 52 Week High
- CCCC $7.22
- TVGN $3.09
- Technical
- Relative Strength Index (RSI)
- CCCC 60.68
- TVGN 35.39
- Support Level
- CCCC $2.57
- TVGN $0.85
- Resistance Level
- CCCC $2.85
- TVGN $0.99
- Average True Range (ATR)
- CCCC 0.19
- TVGN 0.05
- MACD
- CCCC -0.01
- TVGN 0.00
- Stochastic Oscillator
- CCCC 72.88
- TVGN 11.90
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.